“…With issues such as poor infrastructure and limited funding already leading to underutilization of central laboratories in these resource-poor settings (Elbireer et al, 2011 ; Nkengasong et al, 2018 ), there is a growing interest in developing point-of-care techniques to diagnose a variety of diseases. Devices, such as miniaturized bioelectronics and microfluidic tests like the lateral-flow immunoassay (LFA), have received much attention over recent years due to their ease-of-use, portability, and limited need for power (Li et al, 2015 ; Sharma et al, 2015 ; Gumustas et al, 2018 ; Wang et al, 2018 ). However, in comparison to the gold standard laboratory-based tests, these devices are still restricted by their limited sensitivity, indicating an increasing need for enhanced detection capabilities at the point-of-care.…”